Hashmi, H., Hansen, D. K., Peres, L. C., Puglianini, O. C., Freeman, C., De Avila, G., Sidana, S., Shune, L., Sborov, D. W., Davis, J., Wagner, C., Kocoglu, M. H., Atrash, S., Voorhees, P., Simmons, G., Ferreri, C., Kalariya, N., Anderson Jr., L. D., Afrough, A., Dima, D., Khouri, J., McGuirk, J., Locke, F., Baz, R., Patel, K. K. and Alsina, M. (2024) “Factors associated with refractoriness or early progression after idecabtagene vicleucel in patients with relapsed/ refractory multiple myeloma: US Myeloma Immunotherapy Consortium real world experience”, Haematologica. Pavia, Italy, 109(5), pp. 1514-1524. doi: 10.3324/haematol.2023.283888.